Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 18, 2024American Journal of Respiratory and Critical Care MedicineOpen Access

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRatko DjukanovićPBPaul BrinkmanJKJohan Kolmert

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Djukanović et al. (2024) studied this question.

synapsesocial.com/papers/68e6e8a8b6db6435876635c7https://doi.org/10.1164/rccm.202310-1730oc
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B22-05 Toward Precision Biologic Selection: Metabolite Ratios Predict Omalizumab Response in Severe Asthma2026
  2. 2Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients2024
  3. 3The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis2026
  4. 4Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma2004 · 652 citations
  5. 5Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period2024